Tango Therapeutics (TNGX) Competitors

Tango Therapeutics logo
$24.17 -1.33 (-5.22%)
Closing price 04:00 PM Eastern
Extended Trading
$24.20 +0.03 (+0.12%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TNGX vs. ASND, BBIO, SMMT, HALO, and KYMR

Should you buy Tango Therapeutics stock or one of its competitors? Tango Therapeutics's main competitors and comparable companies include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Summit Therapeutics (SMMT), Halozyme Therapeutics (HALO), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tango Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Ascendis Pharma A/S has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

In the previous week, Tango Therapeutics had 5 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 34 mentions for Tango Therapeutics and 29 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.69 beat Tango Therapeutics' score of -0.02 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascendis Pharma A/S
7 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Tango Therapeutics
8 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ascendis Pharma A/S presently has a consensus price target of $313.52, suggesting a potential upside of 13.85%. Tango Therapeutics has a consensus price target of $45.54, suggesting a potential upside of 78.58%. Given Tango Therapeutics' higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascendis Pharma A/S
0 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.90
Tango Therapeutics
2 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.65

79.0% of Tango Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tango Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Tango Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$814.57M21.09-$258M$15.3018.00
Tango Therapeutics$62.38M69.27-$101.59M-$1.37N/A

Ascendis Pharma A/S has a net margin of 73.26% compared to Tango Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.47% beat Tango Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascendis Pharma A/S73.26% 32.47% 13.26%
Tango Therapeutics N/A -30.34%-28.28%

Summary

Ascendis Pharma A/S beats Tango Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

BridgeBio Pharma currently has a consensus price target of $104.42, indicating a potential upside of 33.36%. Tango Therapeutics has a consensus price target of $45.54, indicating a potential upside of 78.58%. Given Tango Therapeutics' higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.82
Tango Therapeutics
2 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.65

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

In the previous week, Tango Therapeutics had 22 more articles in the media than BridgeBio Pharma. MarketBeat recorded 34 mentions for Tango Therapeutics and 12 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.99 beat Tango Therapeutics' score of -0.02 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Pharma
3 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tango Therapeutics
8 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tango Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$945.54M16.13-$724.93M-$3.04N/A
Tango Therapeutics$62.38M69.27-$101.59M-$1.37N/A

Tango Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -59.84%. BridgeBio Pharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Pharma-59.84% N/A -39.81%
Tango Therapeutics N/A -30.34%-28.28%

Summary

Tango Therapeutics beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Tango Therapeutics has higher revenue and earnings than Summit Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit TherapeuticsN/AN/A-$1.08B-$1.07N/A
Tango Therapeutics$62.38M69.27-$101.59M-$1.37N/A

Tango Therapeutics' return on equity of -30.34% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit TherapeuticsN/A -138.82% -117.11%
Tango Therapeutics N/A -30.34%-28.28%

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 81.8% of Summit Therapeutics shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Tango Therapeutics had 27 more articles in the media than Summit Therapeutics. MarketBeat recorded 34 mentions for Tango Therapeutics and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.99 beat Tango Therapeutics' score of -0.02 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Tango Therapeutics
8 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summit Therapeutics has a beta of -1.49, meaning that its stock price is 249% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Summit Therapeutics currently has a consensus price target of $28.61, suggesting a potential upside of 102.17%. Tango Therapeutics has a consensus price target of $45.54, suggesting a potential upside of 78.58%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Tango Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58
Tango Therapeutics
2 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.65

Summary

Tango Therapeutics beats Summit Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Tango Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Tango Therapeutics had 22 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 34 mentions for Tango Therapeutics and 12 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.13 beat Tango Therapeutics' score of -0.02 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tango Therapeutics
8 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Halozyme Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$1.40B8.19$316.89M$3.9325.51
Tango Therapeutics$62.38M69.27-$101.59M-$1.37N/A

Halozyme Therapeutics has a net margin of 26.93% compared to Tango Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 751.81% beat Tango Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics26.93% 751.81% 23.84%
Tango Therapeutics N/A -30.34%-28.28%

Halozyme Therapeutics presently has a consensus target price of $108.18, suggesting a potential upside of 7.89%. Tango Therapeutics has a consensus target price of $45.54, suggesting a potential upside of 78.58%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
1 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.46
Tango Therapeutics
2 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.65

97.8% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Halozyme Therapeutics beats Tango Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Kymera Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Kymera Therapeutics (NASDAQ:KYMR) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Tango Therapeutics currently has a consensus price target of $45.54, indicating a potential upside of 78.58%. Kymera Therapeutics has a consensus price target of $139.16, indicating a potential upside of 9.09%. Given Tango Therapeutics' higher probable upside, equities research analysts clearly believe Tango Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tango Therapeutics
2 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.65
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.89

79.0% of Tango Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tango Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -22.39% beat Tango Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tango TherapeuticsN/A -30.34% -28.28%
Kymera Therapeutics -285.33%-22.39%-20.48%

Tango Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

In the previous week, Tango Therapeutics had 30 more articles in the media than Kymera Therapeutics. MarketBeat recorded 34 mentions for Tango Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.07 beat Tango Therapeutics' score of -0.02 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tango Therapeutics
8 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kymera Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tango Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tango Therapeutics$62.38M69.27-$101.59M-$1.37N/A
Kymera Therapeutics$102.24M106.53-$311.35M-$3.62N/A

Summary

Kymera Therapeutics beats Tango Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Tango Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNGX vs. The Competition

MetricTango TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4.21B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E RatioN/A26.5532.9127.39
Price / Sales65.6616.028.595.74
Price / CashN/A26.3721.9322.50
Price / Book4.184.074.403.70
Net Income-$101.59M-$22.86M$3.52B$392.17M
7 Day Performance6.29%-7.26%-5.34%-4.53%
1 Month Performance9.66%-4.96%-3.61%-5.86%
1 Year Performance195.84%-2.87%0.01%-7.78%

Tango Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TNGX
Tango Therapeutics
2.7415 of 5 stars
$24.17
-5.2%
$45.54
+88.4%
+212.1%$4.21B$62.38MN/A137
ASND
Ascendis Pharma A/S
4.2447 of 5 stars
$256.79
-1.2%
$305.95
+19.1%
+34.7%$16.00B$814.57M19.891,189
BBIO
BridgeBio Pharma
3.5932 of 5 stars
$79.29
+1.7%
$104.26
+31.5%
+17.9%$15.42B$502.08MN/A839
SMMT
Summit Therapeutics
2.6441 of 5 stars
$17.65
-1.1%
$28.61
+62.1%
-21.5%$14.09BN/AN/A265
HALO
Halozyme Therapeutics
4.26 of 5 stars
$103.30
+0.4%
$106.73
+3.3%
+43.2%$11.74B$1.40B26.33423

Related Companies and Tools


This page (NASDAQ:TNGX) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners